Skip to main content

Immix Biopharma, Inc.

IMMX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001873835

No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Immix Biopharma, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of IMMX: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders1218+6
Shares299.6K440.8K+141.1K (+47.1%)
Value$406.0K$1.01M+$605.3K (+149.1%)

New holders (7)

Institutions that held Immix Biopharma, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to IMMX in Q4 2022
InstitutionSharesValue% of portfolio
Murchinson Ltd.67,200$153.9K0.02%
Boothbay Fund Management, LLC33,600$76.9K0.00%
Lynwood Capital Management Inc.25,000$58.0K0.07%
Moss Adams Wealth Advisors LLC20,000$45.8K0.02%
Bank of Montreal15,000$36.0K0.00%
Two Sigma Securities, LLC12,597$28.8K0.00%
Bank of America Corp10$220.00%

Sold out (1)

Institutions that held Immix Biopharma, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of IMMX in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Renaissance Technologies LLC27,050$37.0K